http://www.iba-protontherapy.com/why-iba

IBA Proton Therapy, Chemin du Cyclotron 3, Louvain-la-Neuve (2026)

04/02/2026

🎗️ Today, on World Cancer Day, we are joining the “Cancer Turned My World Upside Down” challenge, and we remain committed to offering proton therapy to all who could benefit from it.

27/01/2026

Our commercial kickoff in beautiful Mechelen, Belgium, has just come to a close. And what an inspiring few days!
It was a valuable moment to exchange perspectives, strengthen our shared direction, and set priorities for the months ahead.
With a clear focus on impact, we continue to work toward one ambition: expanding access to proton therapy and helping more patients worldwide benefit from it.

27/01/2026

🎉We are thrilled to share that we have signed 𝗮 𝗰𝗼𝗻𝘁𝗿𝗮𝗰𝘁 𝗳𝗼𝗿 𝗮 𝗣𝗿𝗼𝘁𝗲𝘂𝘀𝗢𝗡𝗘 𝗽𝗿𝗼𝘁𝗼𝗻 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝘀𝘆𝘀𝘁𝗲𝗺 𝘁𝗼 MACKAY MEMORIAL HOSPITAL 𝗶𝗻 𝗡𝗲𝘄 𝗧𝗮𝗶𝗽𝗲𝗶 𝗖𝗶𝘁𝘆, 𝗧𝗮𝗶𝘄𝗮𝗻.

Dr. Chun-Hao Chen, MD, PhD, Director of the Department of Radiation Oncology at MacKay Memorial Hospital, stated:
“𝘞𝘦 𝘢𝘳𝘦 𝘱𝘳𝘰𝘶𝘥 𝘵𝘰 𝘱𝘢𝘳𝘵𝘯𝘦𝘳 𝘸𝘪𝘵𝘩 𝘐𝘉𝘈 𝘵𝘰 𝘣𝘳𝘪𝘯𝘨 𝘵𝘩𝘪𝘴 𝘢𝘥𝘷𝘢𝘯𝘤𝘦𝘥 𝘵𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘺 𝘵𝘰 𝘛𝘢𝘪𝘸𝘢𝘯. 𝘛𝘩𝘦 𝘪𝘯𝘴𝘵𝘢𝘭𝘭𝘢𝘵𝘪𝘰𝘯 𝘰𝘧 𝘵𝘩𝘦 𝘗𝘳𝘰𝘵𝘦𝘶𝘴®𝘖𝘕𝘌 𝘴𝘺𝘴𝘵𝘦𝘮 𝘢𝘵 𝘔𝘢𝘤𝘒𝘢𝘺 𝘔𝘦𝘮𝘰𝘳𝘪𝘢𝘭 𝘏𝘰𝘴𝘱𝘪𝘵𝘢𝘭 𝘸𝘪𝘭𝘭 𝘴𝘪𝘨𝘯𝘪𝘧𝘪𝘤𝘢𝘯𝘵𝘭𝘺 𝘦𝘯𝘩𝘢𝘯𝘤𝘦 𝘰𝘶𝘳 𝘢𝘣𝘪𝘭𝘪𝘵𝘺 𝘵𝘰 𝘱𝘳𝘰𝘷𝘪𝘥𝘦 𝘴𝘵𝘢𝘵𝘦-𝘰𝘧-𝘵𝘩𝘦-𝘢𝘳𝘵 𝘤𝘢𝘯𝘤𝘦𝘳 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵 𝘵𝘰 𝘰𝘶𝘳 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴. 𝘛𝘩𝘪𝘴 𝘤𝘰𝘭𝘭𝘢𝘣𝘰𝘳𝘢𝘵𝘪𝘰𝘯 𝘮𝘢𝘳𝘬𝘴 𝘢 𝘮𝘢𝘫𝘰𝘳 𝘮𝘪𝘭𝘦𝘴𝘵𝘰𝘯𝘦 𝘪𝘯 𝘰𝘶𝘳 𝘤𝘰𝘮𝘮𝘪𝘵𝘮𝘦𝘯𝘵 𝘵𝘰 𝘥𝘦𝘭𝘪𝘷𝘦𝘳𝘪𝘯𝘨 𝘸𝘰𝘳𝘭𝘥-𝘤𝘭𝘢𝘴𝘴 𝘤𝘢𝘳𝘦 𝘢𝘯𝘥 𝘦𝘹𝘱𝘢𝘯𝘥𝘪𝘯𝘨 𝘢𝘤𝘤𝘦𝘴𝘴 𝘵𝘰 𝘪𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘷𝘦 𝘵𝘩𝘦𝘳𝘢𝘱𝘪𝘦𝘴 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘭𝘰𝘤𝘢𝘭 𝘤𝘰𝘮𝘮𝘶𝘯𝘪𝘵𝘺.”

This is 𝘁𝗵𝗲 𝗳𝗼𝘂𝗿𝘁𝗵 𝗼𝗿𝗱𝗲𝗿 𝗼𝗳 𝗮 𝗣𝗿𝗼𝘁𝗲𝘂𝘀𝗢𝗡𝗘 𝘀𝘆𝘀𝘁𝗲𝗺 𝗶𝗻 𝗧𝗮𝗶𝘄𝗮𝗻, further reinforcing IBA’s position as the undisputed market leader.

👉 Read the full press release here: https://www.iba-worldwide.com/iba-signs-contract-proteusrone-proton-therapy-system-be-located-mackay-memorial-hospital-new-taipei

27/12/2025

🎉🎉🎉Honored and excited to announce that 𝘄𝗲 𝗵𝗮𝘃𝗲 𝘀𝗶𝗴𝗻𝗲𝗱 𝗮 𝗰𝗼𝗻𝘁𝗿𝗮𝗰𝘁 with 𝗧𝗵𝗲 𝗖𝗮𝘁𝗵𝗼𝗹𝗶𝗰 𝗨𝗻𝗶𝘃𝗲𝗿𝘀𝗶𝘁𝘆 𝗼𝗳 𝗞𝗼𝗿𝗲𝗮, 𝗦𝗲𝗼𝘂𝗹 𝗦𝘁. 𝗠𝗮𝗿𝘆'𝘀 𝗛𝗼𝘀𝗽𝗶𝘁𝗮𝗹, one of South Korea’s largest hospitals!
This agreement includes the installation of a 𝗣𝗿𝗼𝘁𝗲𝘂𝘀®𝗣𝗟𝗨𝗦 solution with 𝘁𝗵𝗿𝗲𝗲 𝗴𝗮𝗻𝘁𝗿𝘆 𝗿𝗼𝗼𝗺𝘀. The system will also include 𝗗𝘆𝗻𝗮𝗺𝗶𝗰𝗔𝗥𝗖®* beam delivery capabilities.
Seoul St. Mary’s Hospital plans to 𝗯𝗲𝗴𝗶𝗻 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗯𝘆 𝘁𝗵𝗲 𝗲𝗻𝗱 𝗼𝗳 𝟮𝟬𝟮𝟵.

👉 Read the full press release: https://www.iba-worldwide.com/iba-signs-contract-three-room-proteusrplus-solution-be-installed-seoul-st-marys-hospital

*DynamicARC® is a registered brand of the IBA’s Proton Arc therapy solution currently under development phase.

19/12/2025

Wishing you happy holidays and a wonderful end of year from all of us at IBA Proton Therapy. ✨

15/12/2025

“𝘛𝘩𝘪𝘴 𝘱𝘶𝘣𝘭𝘪𝘤𝘢𝘵𝘪𝘰𝘯 𝘪𝘯 𝙏𝙝𝙚 𝙇𝙖𝙣𝙘𝙚𝙩 𝘵𝘳𝘶𝘭𝘺 𝘮𝘢𝘳𝘬𝘴 𝘢𝘯 𝙞𝙢𝙥𝙤𝙧𝙩𝙖𝙣𝙩 𝙢𝙞𝙡𝙚𝙨𝙩𝙤𝙣𝙚 𝙛𝙤𝙧 𝙩𝙝𝙚 𝙛𝙞𝙚𝙡𝙙 𝙤𝙛 𝙥𝙧𝙤𝙩𝙤𝙣 𝙧𝙖𝙙𝙞𝙤𝙩𝙝𝙚𝙧𝙖𝙥𝙮. 𝘛𝘩𝘪𝘴 𝘵𝘳𝘪𝘢𝘭 𝘴𝘵𝘢𝘳𝘵𝘦𝘥 𝘮𝘰𝘳𝘦 𝘵𝘩𝘢𝘯 10 𝘺𝘦𝘢𝘳𝘴 𝘢𝘨𝘰 𝘢𝘯𝘥 𝘩𝘢𝘴 𝘳𝘰𝘣𝘶𝘴𝘵 𝘭𝘰𝘯𝘨 𝘵𝘦𝘳𝘮 𝘧𝘰𝘭𝘭𝘰𝘸-𝘶𝘱 𝘥𝘢𝘵𝘢 𝘥𝘦𝘮𝘰𝘯𝘴𝘵𝘳𝘢𝘵𝘪𝘯𝘨 𝘤𝘭𝘦𝘢𝘳 𝙦𝙪𝙖𝙡𝙞𝙩𝙮-𝙤𝙛-𝙡𝙞𝙛𝙚 𝙗𝙚𝙣𝙚𝙛𝙞𝙩𝙨 𝘧𝘰𝘳 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘣𝘦𝘪𝘯𝘨 𝘵𝘳𝘦𝘢𝘵𝘦𝘥 𝘸𝘪𝘵𝘩 𝘱𝘳𝘰𝘵𝘰𝘯 𝘵𝘩𝘦𝘳𝘢𝘱𝘺 𝘢𝘴 𝘸𝘦𝘭𝘭 𝘢𝘴 𝘢 𝙧𝙚𝙙𝙪𝙘𝙚𝙙 𝙝𝙖𝙯𝙖𝙧𝙙 𝙤𝙛 𝙙𝙚𝙖𝙩𝙝 𝙤𝙛 42%. 𝘛𝘩𝘦 𝘱𝘶𝘣𝘭𝘪𝘤𝘢𝘵𝘪𝘰𝘯 𝘪𝘴 𝘢𝘯 𝘪𝘮𝘱𝘰𝘳𝘵𝘢𝘯𝘵 𝘭𝘢𝘯𝘥𝘮𝘢𝘳𝘬 𝘵𝘰 𝘵𝘳𝘢𝘯𝘴𝘧𝘰𝘳𝘮 𝙥𝙧𝙤𝙩𝙤𝙣 𝙩𝙝𝙚𝙧𝙖𝙥𝙮 𝘪𝘯𝘵𝘰 𝘵𝘩𝘦 𝙣𝙚𝙬 𝙨𝙩𝙖𝙣𝙙𝙖𝙧𝙙 𝙤𝙛 𝙘𝙖𝙧𝙚 𝘧𝘰𝘳 𝘵𝘩𝘰𝘴𝘦 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴.” Luk Herremans, Chief Market Officer of IBA Proton Therapy.

On December 11, The Lancet, one of the world’s most renowned academic journals, published a landmark study that recommends proton therapy as a new standard of care for patients with oropharyngeal cancer. This study, led by MD Anderson Cancer Center, the world’s leading hospital for cancer care, is the first-ever randomized controlled trial (RCT) to provide the highest level of evidence demonstrating the benefits of proton therapy over conventional radiotherapy for this indication.

👉 Read the full press release here: https://lnkd.in/ezumstmX

12/12/2025

📢 Today, 𝗧𝗵𝗲 𝗟𝗮𝗻𝗰𝗲𝘁 has released a groundbreaking study 𝗿𝗲𝗰𝗼𝗺𝗺𝗲𝗻𝗱𝗶𝗻𝗴 𝗽𝗿𝗼𝘁𝗼𝗻 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗮𝘀 𝗮 𝗻𝗲𝘄 𝘀𝘁𝗮𝗻𝗱𝗮𝗿𝗱-𝗼𝗳-𝗰𝗮𝗿𝗲 for patients with oropharyngeal cancer.

Oropharyngeal cancer is a globally increasing cancer with 𝟭𝟬𝟬.𝟬𝟬𝟬+ 𝗻𝗲𝘄 𝗰𝗮𝘀𝗲𝘀 𝗽𝗲𝗿 𝘆𝗲𝗮𝗿*. When treated with advanced photon-based radiotherapy (IMRT) and chemotherapy, 𝗺𝗮𝗷𝗼𝗿 𝘀𝗶𝗱𝗲 𝗲𝗳𝗳𝗲𝗰𝘁𝘀 include weight loss, feeding tubes dependence, dry mouth and loss of taste.

This study provides 𝗹𝗲𝘃𝗲𝗹 𝟭 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲 with following main conclusions:

● 𝗦𝗶𝗴𝗻𝗶𝗳𝗶𝗰𝗮𝗻𝘁 𝗶𝗺𝗽𝗿𝗼𝘃𝗲𝗺𝗲𝗻𝘁 𝗶𝗻 𝗼𝘃𝗲𝗿𝗮𝗹𝗹 𝘀𝘂𝗿𝘃𝗶𝘃𝗮𝗹 with the overall survival rate of 90.9% at 5 years after IMPT versus 81.0% after IMRT (p=0.045)

● 𝗥𝗲𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝘁𝗵𝗲 𝗵𝗮𝘇𝗮𝗿𝗱 𝗼𝗳 𝗱𝗲𝗮𝘁𝗵 𝗯𝘆 𝟰𝟮%

● 𝗦𝗶𝗴𝗻𝗶𝗳𝗶𝗰𝗮𝗻𝘁𝗹𝘆 𝗿𝗲𝗱𝘂𝗰𝗲𝗱 𝗿𝗮𝘁𝗲𝘀 𝗼𝗳 𝘀𝗲𝘃𝗲𝗿𝗲 𝘁𝗼𝘅𝗶𝗰𝗶𝘁𝗶𝗲𝘀 (grade 3 and worse) compared to IMRT. Toxicities include lymphopenia, neutropenia, xerostomia, dysphagia, and gastrotomy-tube dependance.

These findings position 𝗽𝗿𝗼𝘁𝗼𝗻 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 as a 𝗴𝗮𝗺𝗲-𝗰𝗵𝗮𝗻𝗴𝗶𝗻𝗴, 𝘀𝗮𝗳𝗲, 𝗮𝗻𝗱 𝗽𝗮𝘁𝗶𝗲𝗻𝘁-𝗳𝗼𝗰𝘂𝘀𝗲𝗱 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻, ready to transform the global standard of care for oropharyngeal cancer.

The trial brought together 𝟮𝟬+ 𝗶𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗶𝗼𝗻𝘀 and involved 𝟰𝟰𝟬 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀. It is the 𝗳𝗶𝗿𝘀𝘁 𝗲𝘃𝗲𝗿 𝗹𝗲𝘃𝗲𝗹 𝟭 𝗿𝗮𝗻𝗱𝗼𝗺𝗶𝘇𝗲𝗱 𝗽𝗵𝗮𝘀𝗲 𝟯 𝘁𝗿𝗶𝗮𝗹 comparing IMPT with IMRT for oropharyngeal cancer.

IBA congratulates Prof. Steven Frank, principal investigator of the MD Anderson Cancer Center Clinical Trial Consortium, and all the involved institutions and experts who made this landmark trial possible.

“𝘛𝘩𝘪𝘴 𝘦𝘷𝘪𝘥𝘦𝘯𝘤𝘦 𝘴𝘩𝘰𝘸𝘴 𝘵𝘩𝘢𝘵 𝘐𝘔𝘗𝘛 𝘪𝘴 𝘢 𝘯𝘦𝘸 𝘴𝘵𝘢𝘯𝘥𝘢𝘳𝘥-𝘰𝘧-𝘤𝘢𝘳𝘦 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵 𝘰𝘱𝘵𝘪𝘰𝘯 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘮𝘢𝘯𝘢𝘨𝘦𝘮𝘦𝘯𝘵 𝘰𝘧 𝘰𝘳𝘰𝘱𝘩𝘢𝘳𝘺𝘯𝘨𝘦𝘢𝘭 𝘵𝘶𝘮𝘰𝘶𝘳𝘴.”

👉 Read the full article here: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01962-2/abstract

*https://gco.iarc.fr/en

UT MD ANDERSON CANCER CENTER, MD Anderson Cancer Center, Massachusetts General Hospital, Mayo Clinic, Memorial Sloan Kettering Cancer Center, Miami Cancer Institute, Karmanos Cancer Institute, Inova Health, Willis Knighton Health, University of Alabama at Birmingham, University of Maryland, University of Washington, University of Pennsylvania, Northwestern University - The Feinberg School of Medicine, University of Oklahoma, University of Florida, The University of Texas MD Anderson Cancer Center, Harvard University, New York Proton Center, UTHealth Houston
The Lancet Group
Annual Conference of the Particle Therapy Cooperative Group (PTCOG), The National Association for Proton Therapy, European Society for Radiotherapy and Oncology (ESTRO), American Society for Radiation Oncology (ASTRO)

09/12/2025

✨ Big news from IBA Proton Therapy! ✨

We are thrilled to announce that YAS Healthcare has signed a contract for a Proteus®ONE solution, the first proton therapy system to be installed in Dubai, UAE !

With the acquisition of this Proteus®ONE system, YAS Healthcare will establish the Gulf Cooperation Council (GCC) region’s first operational proton therapy center, marking a major milestone in advancing cancer treatment in the UAE and beyond.

🤝 Together with YAS, we’re committed to making proton therapy technology available for the benefit of the patients in this region. This new contract demonstrates the technological advancement of the IBA offering on the market.

Welcome to our Proton Therapy Community! 🚀

Read the press release : https://www.iba-worldwide.com/yas-healthcare-signs-contract-proteusrone-solution-first-proton-therapy-system-be-installed-dubai

30/10/2025

🌸🎗 “It’s a huge trial. 1,239 patients is the largest randomized proton versus photon trial. We’re very grateful to the patients that trusted us with their care and were willing to enroll on this trial to help other patients and help further research.”

As we conclude our Breast Cancer Awareness Month series, Dr. Shannon MacDonald, the clinical chair of RadComp and medical director of the Southwest Florida Proton Center, reflects on the impact of this trial. Progress in cancer care is only possible thanks to the patients, clinicians, and researchers who make it happen.

S.M. MacDonald & Al. - Phase III randomized trial of proton vs. photon therapy for patients with non-metastatic breast cancer receiving comprehensive nodal radiation: A radiotherapy comparative effectiveness (RadComp) Consortium Trial: Health-related quality of life outcomes - ASTRO2025).

👉 Watch the full series on our YouTube channel to see how proton therapy is advancing breast cancer treatment: https://www.youtube.com/watch?si=PWdwSScesAPsmeuo&v=jO4GXYcqZnQ&feature=youtu.be

hashtag hashtag hashtag hashtag

28/10/2025

🌸🎗 “I think those that would benefit most (from proton therapy) are left sided, medial tumors, and odd chest wall anatomy patients that can't lift their arms above their head […] and those that might have hearts that are close by their chest wall”

Continuing our Breast Cancer Awareness Month series, Dr. Shannon MacDonald, the clinical chair of RadComp and medical director of the Southwest Florida Proton Center, shares her perspective on which patients can benefit most from proton therapy in breast cancer treatment.

(S.M. MacDonald & Al. - Phase III randomized trial of proton vs. photon therapy for patients with non-metastatic breast cancer receiving comprehensive nodal radiation: A radiotherapy comparative effectiveness (RadComp) Consortium Trial: Health-related quality of life outcomes -ASTRO2025).

👉 Watch the full series on our YouTube channel to see how proton therapy is advancing breast cancer treatment: https://lnkd.in/eR-TXtkh

hashtag hashtag hashtag hashtag

22/10/2025

🌸🎗 “Our first outcome is health-related quality of life. We know that patient-reported outcomes and quality of life are extremely important. Our patients know more than we do about how they feel, and learning directly from them is often more meaningful.”

As we continue our series for the Breast Cancer Awareness Month, Dr. Shannon MacDonald, the clinical chair of RadComp and medical director of the Southwest Florida Proton Center, discusses the key outcomes studied in the RadComp breast cancer proton therapy trial focusing on quality of life and patient-reported experiences.

(S.M. MacDonald & Al. - Phase III randomized trial of proton vs. photon therapy for patients with non-metastatic breast cancer receiving comprehensive nodal radiation: A radiotherapy comparative effectiveness (RadComp) Consortium Trial: Health-related quality of life outcomes -ASTRO2025).

👉 Watch the full series on our YouTube channel to see how proton therapy is advancing breast cancer treatment: https://www.youtube.com/watch?si=LDma2jg2acd_ZuFG&v=tsyU-No-EM0&feature=youtu.be

21/10/2025

A must-attend event for the scientific community:

The latest results from a randomized multicenter Phase III study comparing Intensity-Modulated Proton Therapy (IMPT) with Intensity-Modulated Photon Therapy (IMRT) in the treatment of oropharyngeal carcinoma will be presented.

Special guest:
Steven J. Frank, Professor in the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center, Houston (Texas).

🗓️ November 13, 2025 | 12:00 – 14:00
📌 Starhotels Metropole, Via Principe Amedeo 3, Rome

Register here: https://form.jotform.com/252881701012347

IBA Proton Therapy

04/02/2026

27/01/2026

27/01/2026

27/12/2025

19/12/2025

15/12/2025

12/12/2025

09/12/2025

30/10/2025

28/10/2025

22/10/2025

21/10/2025

Adres

Website

Meldingen

Contact De Praktijk

Snelkoppelingen

Delen

Type